Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Study of Entinostat in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Sponsor:Children's Oncology Group
Enrolling:Male and Female Patients
Age Range:Between 1 and 21 years old
IRB Number:AAAR2008
U.S. Government ID:NCT02780804
Contact: Rebecca Zylber, NP: 212-305-7212 /
Additional Study Information:

This study is being carried out by the Childrens Oncology Group (COG) Phase 1 Consortium. COG is an international research group that consists of more than 200 hospitals that treat children with cancer in the United States, Canada, Australia, and Switzerland. The Phase 1 Consortium is the group within COG that consists of 21 hospitals, and participation in this study will be limited to these hospitals. This is a Phase 1 study of a drug called entinostat. Entinostat is considered experimental because it has not been proven to work in a situation like yours. We are using entinostat because it seems to work against cancer in test tubes and animals. Entinostat has been used in adults, but there is a lot that we do not know about it yet. This is called a Phase 1 study because the goal is to find the highest dose of entinostat that we can give safely. We are testing new experimental drugs such as entinostat in the hopes of finding a treatment that may be effective against tumors or lymphoma that have come back or that have not responded to standard therapy.

This study is closed
Alice Lee, MD
You may be eligible for this study

Place Holder

Who Can I Contact?
For more information, please contact:
Rebecca Zylber, NP
Phone: 212-305-7212